,Clusters,ID,Description,GeneRatio,BgRatio,pvalue,p.adjust,qvalue,geneID,Count
1,1,WP3959,DNA IR-double strand breaks and cellular response via ATM,10/247,55/7850,6.66E-06,0.002272527,0.001229472,7158/55183/9656/545/4361/1869/10413/7157/4683/10155,10
2,1,WP4016,DNA IR-damage and cellular response via ATR,12/247,83/7850,9.60E-06,0.003275135,0.001229472,5965/7158/9656/545/4361/1869/84142/7157/4683/10155/11073/5371,12
3,1,WP5049,Glycolysis in senescence,5/247,Nov-50,1.17E-05,0.003996195,0.001229472,5925/2597/7157/5315/3939,5
4,1,WP411,mRNA processing,15/247,133/7850,1.69E-05,0.005766229,0.001330531,6433/9129/10250/6427/22803/11218/57794/5430/10772/6430/8899/55660/10914/23451/11129,15
5,1,WP1984,Integrated breast cancer pathway,16/247,155/7850,2.71E-05,0.009252073,0.001707899,5058/23613/2355/545/5925/5284/4361/1869/994/7248/7157/1022/80271/6772/466/5371,16
6,1,WP3651,Pathways affected in adenoid cystic carcinoma,10/247,66/7850,3.55E-05,0.012092448,0.001860185,7403/1387/10847/546/7994/51742/58508/2064/7157/29072,10
7,1,WP437,EGF/EGFR signaling pathway,16/247,164/7850,5.44E-05,0.018547341,0.002445551,5782/5058/6311/4605/5579/30011/1869/2064/1978/54206/29924/10746/9712/6772/466/6195,16
8,1,WP1971,Integrated cancer pathway,8/247,46/7850,7.94E-05,0.027079221,0.003124204,545/5925/4361/1869/994/7157/6772/466,8
9,2,WP51,Regulation of actin cytoskeleton,21/228,151/7850,1.96E-09,7.27E-07,6.63E-07,4638/8826/2909/5287/5595/8396/8394/9459/5829/10458/8874/4659/2147/10152/4478/5747/85464/4628/7114/324/30849,21
10,2,WP3888,VEGFA-VEGFR2 signaling pathway,33/228,439/7850,3.72E-07,0.000138381,4.35E-05,8650/1500/8826/1397/9100/2060/2035/5590/5595/6461/1213/2889/5829/2317/2746/8667/3725/100506658/2308/2624/5230/2549/3315/22899/5747/152273/9252/7114/84952/4303/4301/4627/3045,33
11,2,WP4560,MFAP5 effect on permeability and motility of endothelial cells via cytoskeleton rearrangement,7/228,18/7850,3.85E-07,0.000143365,4.35E-05,4638/7082/4026/5595/5829/3725/5747,7
12,2,WP481,Insulin signaling,17/228,161/7850,3.84E-06,0.001427956,0.00032527,2319/5590/3636/6196/5595/2889/3725/6446/2308/2549/8773/8986/9252/7249/10580/5871/30849,17
13,2,WP306,Focal adhesion,17/228,202/7850,7.56E-05,0.028113139,0.004450827,7094/4638/2316/54776/83660/2909/7791/5595/4660/2889/5829/2317/3725/4659/2318/5747/29780,17
14,2,WP437,EGF/EGFR signaling pathway,15/228,164/7850,7.88E-05,0.029309111,0.004450827,8826/2060/5590/5287/3636/6196/5782/6776/3725/2308/2549/10253/5747/9252/4303,15
15,3,WP3888,VEGFA-VEGFR2 signaling pathway,67/562,439/7850,1.32E-09,5.96E-07,4.93E-07,226/4773/5710/23196/4641/9898/3065/4646/2317/10130/4790/1495/4673/2060/4627/57326/84335/5584/5770/27044/811/4691/1500/26058/54505/10628/6386/4208/5578/9100/9759/357/1387/253260/3320/9578/2309/5777/55854/71/2475/25865/8575/4217/1072/7024/3303/4772/5580/8569/154796/1982/813/5034/8411/31/6464/1386/7086/51574/1981/7430/115098/7001/6774/2534/10397,67
16,3,WP411,mRNA processing,29/562,133/7850,4.21E-08,1.90E-05,7.87E-06,51362/10181/7307/3192/10291/22803/10421/3184/1659/6625/4670/3188/4809/6626/3183/6429/27316/3187/8899/3182/10772/3191/57396/23451/56339/10914/8449/10250/6637,29
17,3,WP3651,Pathways affected in adenoid cystic carcinoma,18/562,66/7850,4.97E-07,0.000224789,6.19E-05,9611/4149/546/55914/23269/1387/29072/2309/58508/221037/51742/5728/284058/10847/84159/5591/7994/4613,18
18,3,WP3878,ATM signaling in development and disease ,13/562,46/7850,1.27E-05,0.005754229,0.001189306,3150/7158/4790/55183/56254/9656/9759/2475/4217/5591/10155/7249/1386,13
19,3,WP138,Androgen receptor signaling pathway,19/562,91/7850,1.79E-05,0.008098951,0.001339137,9611/3065/56924/10273/8202/23028/8031/24149/811/10499/1387/2316/5728/1956/9612/5925/5883/25942/6774,19
20,3,WP4255,Non-small cell lung cancer,16/562,72/7850,3.66E-05,0.016521965,0.002276548,1869/27436/572/841/5578/673/2309/1956/5336/1643/369/5925/6654/6774/208/6655,16
21,3,WP4320,Effect of progerin on genes involved in Hutchinson-Gilford progeria syndrome,11/562,39/7850,6.06E-05,0.027412354,0.003186019,1108/3066/3065/1869/23028/11335/5931/10951/9112/9219/5925,11
22,3,WP481,Insulin signaling,26/562,161/7850,6.82E-05,0.030829897,0.003186019,10487/4641/5584/5770/4296/9882/8986/5578/5583/2309/2475/4217/5728/5580/3667/7249/6464/2888/9448/8660/4214/6654/2997/208/6655/2992,26
23,3,WP437,EGF/EGFR signaling pathway,26/562,164/7850,9.37E-05,0.042339339,0.003469237,1869/2060/2059/8202/6311/5584/3635/5287/4208/5578/253260/673/2475/1173/5728/1072/58513/9185/1956/5580/6464/4214/6654/5782/6774/6655,26
24,3,WP585,Interferon type I signaling pathways,13/562,55/7850,9.98E-05,0.045106528,0.003469237,1975/3455/8986/5777/2475/3667/6773/5966/8660/4214/5788/6774/2534,13
25,3,WP4949,16p11.2 proximal deletion syndrome,16/562,78/7850,0.000102123,0.046159414,0.003469237,226/143/4790/57223/8085/55671/8479/841/11151/2186/58508/5728/10497/5966/8030/7430,16
26,4,WP3651,Pathways affected in adenoid cystic carcinoma,21/502,66/7850,3.30E-10,1.44E-07,1.21E-07,2033/55914/9611/54880/5605/23269/2309/284058/58508/84159/8289/10847/546/221037/7994/11200/29072/63035/1387/64324/9874,21
27,4,WP411,mRNA processing,27/502,133/7850,5.78E-08,2.51E-05,1.06E-05,23451/1478/3187/8899/3192/3190/6428/3184/4841/6829/3181/6421/6434/6430/3178/10250/22803/27316/1198/5430/84991/9584/8683/6426/29894/10772/3191,27
28,4,WP437,EGF/EGFR signaling pathway,28/502,164/7850,1.42E-06,0.000616679,0.000167558,6654/253260/6655/2059/5605/8027/30011/4208/25/9712/6198/10006/868/9101/8202/5335/1432/1759/6311/3635/29924/4214/4209/5598/1956/5782/9564/160,28
29,4,WP3888,VEGFA-VEGFR2 signaling pathway,54/502,439/7850,1.82E-06,0.000793619,0.000167558,357/55692/253260/2926/6461/4773/5605/8027/2309/10755/5499/4208/1982/25/9645/1500/154796/6198/54505/102/1827/10818/57326/56905/5335/1432/26058/29924/23215/1981/1499/4301/9584/56907/9451/10397/2889/1387/9759/100506658/23196/8650/4217/6142/9898/9564/2081/4790/1386/1495/11124/51564/160/9578,54
30,4,WP3878,ATM signaling in development and disease ,13/502,46/7850,3.69E-06,0.0016068,0.000271397,7158/7249/3150/55183/9656/3930/11200/64421/8517/9759/4217/4790/1386,13
31,4,WP3915,Angiopoietin-like protein 8 regulatory pathway,23/502,132/7850,8.77E-06,0.003814983,0.000536975,6654/8660/8986/253260/4296/6655/7249/5605/2309/3667/9064/6198/868/4294/1432/4214/6199/5598/2889/10211/2997/57521/4217,23
32,4,WP3414,Initiation of transcription and translation elongation at the HIV-1 LTR,11/502,37/7850,1.22E-05,0.00530877,0.000640484,2033/4773/7936/6829/4775/7469/1387/9759/4776/4790/51564,11
33,4,WP366,TGF-beta signaling pathway,22/502,133/7850,3.19E-05,0.013880585,0.001465313,2033/3691/9972/6654/4233/79753/5605/4208/5934/9765/55802/5371/1432/25942/23327/22938/3726/1387/57559/64219/9564/1386,22
34,4,WP23,B cell receptor signaling pathway,18/502,98/7850,4.02E-05,0.017478013,0.001640069,6654/4773/604/5605/4208/29760/5335/2969/4775/1432/6452/3635/84433/8517/4209/2889/4790/1386,18
35,4,WP4321,Thermogenesis,19/502,108/7850,4.60E-05,0.020022747,0.001690971,6654/57492/6655/6597/7249/6603/8289/51780/6198/6601/10818/51548/1432/55818/6199/57521/4217/63976/1386,19
36,4,WP4549,Fragile X syndrome,20/502,123/7850,9.29E-05,0.040430702,0.003104068,9743/6654/10243/4131/7249/5605/5499/369/6198/4763/5335/116986/1759/1605/1981/23426/6895/57521/64798/160,20
37,4,WP2380,Brain-derived neurotrophic factor (BDNF) signaling pathway,22/502,144/7850,0.000109728,0.047731474,0.003359202,8660/4137/7249/5605/2309/3667/4208/6198/324/10818/8878/5335/1432/4214/8517/5598/23426/1499/57498/4776/249/4790,22
38,5,WP3651,Pathways affected in adenoid cystic carcinoma,17/456,66/7850,1.29E-07,5.36E-05,4.54E-05,23269/5894/1387/29072/58508/55914/2033/7403/546/221037/2309/10847/4149/5591/8243/9223/9611,17
39,5,WP2380,Brain-derived neurotrophic factor (BDNF) signaling pathway,25/456,144/7850,6.60E-07,0.000273697,0.000115935,5894/3667/10746/8894/7074/2932/1739/1965/4905/836/23191/5295/10018/1072/3725/8660/2309/6777/324/6792/6776/1808/4214/32/1499,25
40,5,WP437,EGF/EGFR signaling pathway,26/456,164/7850,2.37E-06,0.000983695,0.000277788,5894/2060/11184/10746/30011/3635/1398/6311/253260/6654/5295/1072/5868/3725/9610/6777/6776/8867/10253/673/4215/5782/4214/3636/4216/58513,26
41,5,WP314,Fas ligand pathway and stress induction of heat shock proteins,12/456,44/7850,4.90E-06,0.002032201,0.000364593,84823/8767/397/836/11124/3725/1616/4214/4000/5591/6885/4001,12
42,5,WP3888,VEGFA-VEGFR2 signaling pathway,49/456,439/7850,5.90E-06,0.002448891,0.000364593,4627/3320/5894/2060/55854/1387/100506658/23215/357/2932/1398/253260/9645/226/5216/2926/154796/660/23476/84790/5295/11124/51574/5777/5499/25865/1072/5868/3725/9759/213/9659/2309/54505/1500/170506/8867/51564/23189/5784/8411/23196/10397/4673/832/22820/5226/32/1499,49
43,5,WP3915,Angiopoietin-like protein 8 regulatory pathway,22/456,132/7850,6.22E-06,0.00258217,0.000364593,5894/3667/11184/10746/10487/5597/2932/1398/253260/6654/7248/5295/8660/2309/9448/4296/50488/4215/4214/6885/10211/4216,22
44,5,WP481,Insulin signaling,24/456,161/7850,1.70E-05,0.007072835,0.000855993,5894/3667/11184/10746/10487/5597/2932/1398/3799/6654/7248/5295/3725/8660/2309/9448/4296/50488/4215/4214/6885/3636/10211/4216,24
45,5,WP4537,Hippo-Yap signaling pathway,8/456,23/7850,2.75E-05,0.011427103,0.001180858,10971/11184/6788/9448/26524/9113/50488/10397,8
46,5,WP304,Kit receptor signaling pathway,13/456,60/7850,3.02E-05,0.012544846,0.001180858,5894/2886/3635/1398/2033/6654/5295/5777/2309/6777/6776/4067/4286,13
47,5,WP2038,Microtubule cytoskeleton regulation,11/456,49/7850,8.77E-05,0.036388842,0.003082783,4131/7074/2932/10420/7204/324/2011/90102/1808/6249/57551,11
48,6,WP411,mRNA processing,18/113,133/7850,3.59E-13,6.46E-11,6.20E-11,23451/10914/10992/10250/10921/55660/8899/9129/6434/6431/57794/23405/22803/8449/10772/9584/6427/3183,18
49,6,WP107,Translation factors,8/113,54/7850,8.62E-07,0.000155123,7.44E-05,8893/1933/9669/1938/1915/8890/8663/1975,8
50,7,WP437,EGF/EGFR signaling pathway,22/293,164/7850,1.58E-07,5.69E-05,5.24E-05,9712/4215/4303/2697/7410/4205/1385/51196/2475/4209/3727/10253/9922/5037/6195/25/2549/6093/10006/3636/5747/4690,22
51,7,WP3888,VEGFA-VEGFR2 signaling pathway,36/293,439/7850,5.87E-06,0.002119159,0.000976315,2243/2624/100506658/6461/152273/4301/4303/2697/4772/7410/84952/5829/1500/91624/1385/5784/5062/357/29109/10014/51564/2475/6595/9475/71/10645/25/2317/2549/9209/6093/355/5747/4690/6624/10818,36
52,7,WP2038,Microtubule cytoskeleton regulation,9/293,49/7850,6.85E-05,0.024741774,0.007599165,90102/814/57551/10420/2011/25/6093/7074/324,9
53,7,WP185,Integrin-mediated cell adhesion,13/293,104/7850,0.000120854,0.043628414,0.010049992,7145/10580/7791/7410/5829/5062/1793/9475/9815/7094/8874/6093/5747,13
54,8,WP185,Integrin-mediated cell adhesion,13/189,104/7850,1.09E-06,0.000327309,0.000242667,7145/7414/5062/2889/9815/10580/5747/5829/1793/857/5058/10000/3611,13
55,8,WP3888,VEGFA-VEGFR2 signaling pathway,28/189,439/7850,1.82E-06,0.000548543,0.000242667,4301/5784/7414/4217/4691/5062/2889/152273/4303/84952/1500/357/71/5777/8650/29766/4772/2035/9209/5747/4690/5829/11080/9513/1397/857/5590/5058,28
56,8,WP51,Regulation of actin cytoskeleton,15/189,151/7850,3.11E-06,0.000936888,0.00027631,10458/7414/5062/4638/71/5747/5829/1793/6548/22800/10152/9459/5058/324/7454,15
57,8,WP306,Focal adhesion,16/189,202/7850,2.67E-05,0.008039789,0.001778341,10188/7414/394/5062/2889/4638/71/83660/2316/5747/5829/1793/857/5058/10000/3611,16
58,8,WP4560,MFAP5 effect on permeability and motility of endothelial cells via cytoskeleton rearrangement,5/189,18/7850,5.09E-05,0.015334587,0.002713517,7414/4638/7082/5747/5829,5
59,8,WP2572,Primary focal segmental glomerulosclerosis (FSGS),9/189,74/7850,6.44E-05,0.019373162,0.002856799,11346/7414/64423/5747/4690/7431/7402/1027/3611,9
60,9,WP3888,VEGFA-VEGFR2 signaling pathway,89/657,439/7850,5.73E-16,2.81E-13,2.22E-13,213/9444/56907/2475/2317/9564/7414/84952/301/4627/83737/6595/1495/23215/2113/5515/4629/5829/3146/23476/1500/100506658/8826/9659/29924/2697/6093/10014/170506/2314/5578/51564/160/4303/5581/4790/71/6722/79109/832/2185/4772/4690/5587/1267/5335/2549/4641/6461/6386/152273/5230/5321/29766/56905/7430/8867/2889/6464/1387/207/5879/2309/23189/1465/9209/5784/25865/8775/5894/9513/3301/1969/4301/55692/8013/2060/9100/2243/4846/1072/5584/9759/55854/4217/5226/5777/5592/4773,89
61,9,WP437,EGF/EGFR signaling pathway,44/657,164/7850,1.24E-12,6.11E-10,2.42E-10,30011/2475/9922/9564/9610/83737/9846/4215/8826/9712/50807/29924/2697/6093/5578/3727/6654/9046/6311/160/4303/1978/2185/51196/6197/4690/5335/2549/8867/5898/6464/10188/4216/207/5879/8440/1956/5894/5607/2060/9138/4846/1072/5584,44
62,9,WP3651,Pathways affected in adenoid cystic carcinoma,20/657,66/7850,2.18E-07,0.000107211,2.83E-05,8289/546/6595/284058/9874/64324/9223/5591/55534/29072/1387/4781/207/10847/2309/2033/221037/5894/9611/58508,20
63,9,WP4659,Gastrin signaling pathway,27/657,114/7850,4.88E-07,0.000239478,4.74E-05,4296/2475/9564/3667/6925/5829/5566/6093/5578/51564/6654/1978/5581/302/7082/4790/5587/5335/6464/207/5879/2309/25865/1956/5894/3815/1027,27
64,9,WP51,Regulation of actin cytoskeleton,30/657,151/7850,5.88E-06,0.002887971,0.000381363,2909/56924/4638/2934/9564/7414/324/4478/5829/4628/8826/87/1793/6093/6654/54961/28964/71/10298/55740/5286/7430/54434/5962/5879/1956/5894/9138/10163/1072,30
65,9,WP2038,Microtubule cytoskeleton regulation,15/657,49/7850,6.29E-06,0.0030868,0.000381363,1855/7074/90102/324/5566/6093/23332/5578/10420/4139/7204/207/5879/4131/2011,15
66,9,WP231,TNF-alpha signaling pathway,22/657,94/7850,6.87E-06,0.003374542,0.000381363,1326/4215/5515/23118/5708/10010/56957/6654/257397/4790/11035/1387/207/10454/5879/8567/11140/5894/8737/4791/7128/4217,22
67,9,WP4223,Ras signaling,34/657,186/7850,9.73E-06,0.004776142,0.00047229,2782/56924/9610/7074/9846/55770/2113/5566/5578/6654/4303/208/4790/4763/9462/10298/51196/5335/2549/801/5321/5898/64926/115727/6464/207/5879/1956/5894/1969/4301/3815/9771/6789,34
68,9,WP185,Integrin-mediated cell adhesion,23/657,104/7850,1.17E-05,0.005741432,0.00050466,825/56924/7145/9564/7414/10580/823/5829/1793/7791/6093/6654/208/10298/7094/369/9815/2889/6464/207/5879/5894/5607,23
69,9,WP2291,Deregulation of Rab and Rab effector genes in bladder cancer,8/657,16/7850,1.62E-05,0.00795414,0.000629237,79083/25924/94121/23086/5873/8567/94120/83874,8
70,9,WP481,Insulin signaling,30/657,161/7850,2.21E-05,0.010832214,0.000779015,4296/8660/2475/10580/1326/4215/3667/7248/5578/6654/1978/208/6722/8986/6197/2549/4641/5286/2889/6464/4216/8491/207/5879/2309/5894/5607/252983/5584/4217,30
71,9,WP366,TGF-beta signaling pathway,26/657,133/7850,3.29E-05,0.016136817,0.001063795,9564/7048/83737/5933/2113/5371/6935/6093/3727/6654/10413/9839/6711/25942/1316/55802/6464/1387/23327/207/10454/5879/2033/9972/5894/6497,26
72,9,WP2795,Cardiac hypertrophic response,15/657,57/7850,4.67E-05,0.022954094,0.00131323,2475/10014/5578/51564/208/4790/5587/801/207/5879/5894/5607/9759/5592/4773,15
73,9,WP3879,"4-hydroxytamoxifen, Dexamethasone, and Retinoic Acids Regulation of p27 Expression",8/657,18/7850,4.73E-05,0.023240618,0.00131323,4296/2475/7248/1978/207/2872/5894/4217,8
74,9,WP3915,Angiopoietin-like protein 8 regulatory pathway,25/657,132/7850,8.01E-05,0.039311581,0.002073244,4296/8660/2475/1326/4215/3667/7248/51422/6654/1978/208/79109/8986/6197/9322/5286/2889/6464/4216/8491/207/2309/5894/5607/4217,25
75,9,WP524,G13 signaling pathway,12/657,41/7850,8.73E-05,0.042843912,0.002118314,5585/8826/6093/10788/85415/801/57630/10188/4216/5879/9138/1072,12
76,9,WP3844,PI3K-AKT-mTOR signaling pathway and therapeutic opportunities,10/657,30/7850,0.000100932,0.049557847,0.002306135,9821/2475/9776/4303/1978/7942/207/2309/1027/4846,10
77,10,WP585,Interferon type I signaling pathways,16/567,55/7850,9.34E-07,0.000399592,0.000261384,1975/2889/5781/8660/4214/9846/79109/6775/867/3667/8554/3455/57521/8986/7297/6774,16
78,10,WP3888,VEGFA-VEGFR2 signaling pathway,59/567,439/7850,1.74E-06,0.000743495,0.000261384,9475/4217/2889/357/5781/5562/4772/4792/9513/81567/10818/1500/23215/7531/1387/6595/9759/1267/6461/4690/8569/84952/5784/3320/4301/25/2060/79109/56907/23476/8826/2113/10397/832/51564/4627/867/253260/5795/8867/8575/26058/1796/54505/2309/824/9584/6416/23189/4773/84335/5058/2597/4846/6774/2185/2035/100506658/71,59
79,10,WP3915,Angiopoietin-like protein 8 regulatory pathway,26/567,132/7850,2.01E-06,0.000859398,0.000261384,11183/4217/2889/5562/8660/4214/7248/7249/10746/79109/6885/30849/4216/867/253260/3667/23265/57521/2309/8986/4296/6416/50488/51085/11184/9448,26
80,10,WP437,EGF/EGFR signaling pathway,28/567,164/7850,1.48E-05,0.006319445,0.001279069,5781/54206/4214/9922/4690/5287/58513/50807/9846/10746/25/2060/8826/8202/4216/9101/9610/867/253260/8867/10006/3636/30011/5058/11184/4846/6774/2185,28
81,10,WP4537,Hippo-Yap signaling pathway,9/567,23/7850,1.64E-05,0.007009022,0.001279069,10397/7005/23043/9113/50488/4771/60485/11184/9448,9
82,10,WP3651,Pathways affected in adenoid cystic carcinoma,15/567,66/7850,5.35E-05,0.022900418,0.003482561,9874/9611/546/8289/29072/55914/1387/6595/7994/58508/23269/10847/2309/9223/221037,15
83,10,WP481,Insulin signaling,26/567,161/7850,7.91E-05,0.033837348,0.004410673,11183/4217/2889/5781/5562/8660/6810/4214/10580/7248/5211/7249/10746/6885/30849/4216/867/3667/3636/2309/8986/4296/6416/50488/11184/9448,26
84,10,WP4656,Joubert syndrome,16/567,77/7850,9.64E-05,0.041265926,0.004706609,4361/9738/51199/8481/95681/1857/51684/27130/142/79598/57545/56623/5108/5116/1855/9786,16
85,11,WP2446,Retinoblastoma gene in cancer,18/325,88/7850,1.38E-08,5.13E-06,4.76E-06,81620/8819/2956/4173/7153/9126/7465/8030/983/5925/5422/24137/6117/6118/1786/54443/5591/5426,18
86,11,WP4016,DNA IR-damage and cellular response via ATR,16/325,83/7850,2.14E-07,7.95E-05,3.69E-05,51720/8924/7158/4171/10111/983/7398/6117/9656/142/11073/6118/83990/672/5591/1196,16
87,11,WP411,mRNA processing,19/325,133/7850,2.03E-06,0.000755641,0.000233777,6625/10992/3192/27316/3178/7307/1660/10250/6429/6732/10482/4904/2521/10772/1196/6434/55660/3181/10147,19
88,11,WP4946,"DNA repair pathways, full network",17/325,121/7850,8.88E-06,0.003304278,0.000766697,2956/2547/8930/10111/57697/7398/6117/5981/142/6118/83990/672/7515/7374/5395/5591/5426,17
89,11,WP466,DNA replication,9/325,42/7850,4.25E-05,0.01582611,0.002937727,81620/4171/4173/5422/6117/5981/6118/10926/5426,9
90,11,WP107,Translation factors,10/325,54/7850,6.07E-05,0.022588832,0.003494217,8662/1975/8661/9669/1933/8667/1981/1936/9451/1938,10
91,11,WP3878,ATM signaling in development and disease ,9/325,46/7850,9.08E-05,0.033785195,0.004479563,7158/55183/10111/983/9656/4217/3315/3150/5591,9
92,12,WP4932,7q11.23 copy number variation syndrome,12/212,106/7850,2.60E-05,0.008865928,0.008292564,9188/10514/23426/3066/7913/23332/23476/3159/2200/2969/10013/8878,12
93,12,WP4016,DNA IR-damage and cellular response via ATR,10/212,83/7850,7.26E-05,0.024758607,0.011578728,4361/4171/672/63967/7158/5932/8517/83990/5371/10155,10
94,12,WP2446,Retinoblastoma gene in cancer,10/212,88/7850,0.000119801,0.040852107,0.012736727,6595/898/3065/54443/1026/4175/1786/4172/7153/7272,10
95,13,WP411,mRNA processing,29/454,133/7850,3.15E-10,1.37E-07,1.23E-07,3181/23451/6625/8899/53981/10181/4904/10250/10921/10992/11338/3190/10421/4841/6429/6431/3187/6434/1198/140890/8449/84991/1479/10772/4686/6430/9129/3192/3183,29
96,13,WP437,EGF/EGFR signaling pathway,28/454,164/7850,1.83E-07,7.97E-05,3.57E-05,10928/6654/1432/2064/4846/6774/673/3925/2308/1399/3635/4209/8826/9185/9101/30011/1956/5580/10617/6772/29924/5782/1759/4208/6195/3727/2059/9922,28
97,13,WP3888,VEGFA-VEGFR2 signaling pathway,50/454,439/7850,2.31E-06,0.001006413,0.000248501,152273/4773/274/6595/1432/4673/4846/6774/2314/1192/2308/9344/55854/100506658/1981/8826/9898/3065/6416/6386/4217/25865/5580/2317/5331/8575/6772/29924/84952/226/6924/4208/3315/6461/3146/5563/27044/23196/1500/9578/3320/9451/5562/6181/1796/357/55692/10525/26058/7414,50
98,13,WP23,B cell receptor signaling pathway,19/454,98/7850,2.55E-06,0.001109746,0.000248501,4773/6654/3059/1432/673/2308/1399/3635/4209/8394/5580/118788/4775/4208/6452/6195/84433/4067/29760,19
99,13,WP2864,Apoptosis-related network due to altered Notch3 in ovarian cancer,13/454,54/7850,8.52E-06,0.003712746,0.000665103,8878/79092/5585/3065/3309/8531/2065/3315/8767/602/3727/7431/26135,13
100,13,WP304,Kit receptor signaling pathway,13/454,60/7850,2.89E-05,0.012583171,0.001878463,6654/1432/6774/1399/3635/4137/2886/6772/572/6195/1796/4067/3726,13
101,13,WP107,Translation factors,12/454,54/7850,4.48E-05,0.019539402,0.002500213,1975/1983/1933/23277/29904/1981/1938/9669/8663/8893/9451/7458,12
102,14,WP3888,VEGFA-VEGFR2 signaling pathway,71/532,439/7850,1.86E-12,8.69E-10,7.24E-10,226/2060/51564/867/5580/7148/1192/3303/4627/1398/6416/1499/7414/8826/2243/4629/2597/9451/3725/6595/160/4673/5296/5584/6624/6714/2309/23196/9564/2317/7531/355/4303/7086/1213/3315/1386/5581/56907/84952/9659/9645/5605/6722/25865/409/32/3688/22820/4208/29924/213/56905/1796/8550/5829/1387/4773/23189/5058/29109/9209/23215/6093/5216/4690/10818/1827/5579/3301/100506658,71
103,14,WP437,EGF/EGFR signaling pathway,38/532,164/7850,9.06E-12,4.23E-09,1.76E-09,2060/867/5580/9712/3636/5596/1398/8826/3725/160/5296/5584/6714/58513/9564/4303/6197/2005/9922/5605/5598/50807/9846/2059/4208/29924/10188/673/5058/9610/10006/3635/30011/6093/51196/4205/4690/5579,38
104,14,WP366,TGF-beta signaling pathway,30/532,133/7850,2.96E-09,1.38E-06,3.84E-07,5934/6497/5576/79753/9839/5596/6416/3725/10413/55802/5296/6714/9564/25942/3726/1386/7071/5371/5605/8554/1601/3688/6935/4208/6711/1387/2033/9972/6093/4205,30
105,14,WP4659,Gastrin signaling pathway,26/532,114/7850,2.68E-08,1.25E-05,2.61E-06,51564/572/5580/4296/1398/1499/408/7082/3725/5296/6714/2309/9564/329/1386/5581/3551/25865/409/3688/4208/6548/5829/5058/6925/6093,26
106,14,WP304,Kit receptor signaling pathway,17/532,60/7850,2.61E-07,0.00012187,2.03E-05,867/572/4067/4286/1398/9306/5296/6714/2309/3726/6197/5605/9846/1796/2033/3635/5579,17
107,14,WP4018,Clear cell renal cell carcinoma pathways,20/532,87/7850,9.60E-07,0.000448469,6.23E-05,226/55276/7248/57521/2597/5236/7167/6009/4190/3101/230/7249/8536/32/6935/29072/1387/2033/55193/2023,20
108,14,WP185,Integrin-mediated cell adhesion,21/532,104/7850,4.82E-06,0.002252733,0.000268394,5596/1398/7414/208/823/7145/5296/5063/6714/9564/7094/5605/5598/3688/369/1793/5829/673/5058/6093/7791,21
109,14,WP3651,Pathways affected in adenoid cystic carcinoma,16/532,66/7850,5.65E-06,0.002636782,0.000274882,8289/58508/6595/7994/2309/5605/10847/29072/221037/51742/8243/9611/1387/2033/546/4781,16
110,14,WP23,B cell receptor signaling pathway,20/532,98/7850,6.84E-06,0.003196078,0.000293271,867/5580/4067/5596/1398/3725/5296/4775/1386/3551/5605/604/7462/9846/4208/4773/673/3635/4690/5579,20
111,14,WP2261,Glioblastoma signaling pathways,18/532,83/7850,8.09E-06,0.003777028,0.000293271,2956/867/5580/2065/7248/6416/208/5296/5584/6714/2309/4303/7249/5605/369/2033/673/5579,18
112,14,WP51,Regulation of actin cytoskeleton,26/532,151/7850,8.28E-06,0.003868121,0.000293271,10458/8045/324/2909/5596/1398/7414/8826/87/5296/5063/9564/8396/5605/2934/6548/1793/6237/5829/673/5058/28964/6093/5216/10163/4628,26
113,14,WP2380,Brain-derived neurotrophic factor (BDNF) signaling pathway,25/532,144/7850,1.06E-05,0.004968213,0.000345287,4082/572/5580/324/1739/7074/1499/3725/5296/6792/6714/2309/23191/6197/7249/3551/5605/5598/8536/32/4208/1808/4205/4690/10818,25
114,14,WP138,Androgen receptor signaling pathway,18/532,91/7850,3.07E-05,0.014348019,0.000854723,2316/1499/3725/5296/6714/23411/10273/573/25942/8554/23028/10499/9611/1387/2033/11143/6093/7182,18
115,14,WP673,ErbB signaling pathway,18/532,91/7850,3.07E-05,0.014348019,0.000854723,867/572/2065/1398/6416/208/3725/5296/5063/6714/5605/369/673/5058/27/816/4690/5579,18
116,14,WP306,Focal adhesion,30/532,202/7850,3.48E-05,0.016241199,0.000903001,572/7148/2909/2316/1398/1499/7414/87/208/3725/5296/5063/6714/9564/2317/329/7094/10627/3688/1793/5829/10188/673/29780/5058/10420/394/6093/7791/5579,30
117,14,WP4656,Joubert syndrome,16/532,77/7850,4.49E-05,0.020977923,0.001093462,403/153241/9786/4218/5116/2316/22897/79598/6009/142/79848/27130/5108/117177/51199/95681,16
118,14,WP481,Insulin signaling,25/532,161/7850,7.45E-05,0.034774865,0.001705995,867/6813/3799/5580/7248/4296/3636/10938/5596/1398/6416/208/3725/5296/5584/2309/8773/6009/6197/7249/3551/5605/6722/5598/5579,25
119,15,WP437,EGF/EGFR signaling pathway,14/150,164/7850,2.65E-06,0.00074163,0.000512049,6464/50807/5782/5590/2059/1978/1956/1173/2064/9712/2308/4303/5607/9564,14
120,15,WP2324,AGE/RAGE pathway,9/150,66/7850,3.91E-06,0.001094016,0.000512049,249/6464/5321/5590/653361/1956/4478/2308/4303,9
121,16,WP411,mRNA processing,43/347,133/7850,2.09E-26,7.69E-24,7.23E-24,10772/8899/55660/23405/9129/10291/51692/10946/10992/23450/6429/10250/4904/11218/9785/9584/10147/1195/6431/6434/1659/6433/6633/4670/3183/3178/6732/27316/3182/57794/6625/2521/11129/1196/22803/8243/6430/6427/1660/6421/23451/10914/8683,43
122,16,WP107,Translation factors,12/347,54/7850,2.94E-06,0.001080524,0.000508263,8894/1933/1936/1938/7458/23277/9669/26986/8665/1978/8663/8662,12
123,16,WP3651,Pathways affected in adenoid cystic carcinoma,12/347,66/7850,2.62E-05,0.0096033,0.003011504,23269/672/29072/546/84159/64324/2064/58508/7157/8243/29128/10847,12
124,16,WP2363,Gastric cancer network 2,8/347,33/7850,7.07E-05,0.025932028,0.006099028,3930/10153/55593/7157/92140/25909/29028/157769,8
125,17,WP437,EGF/EGFR signaling pathway,25/257,164/7850,9.07E-11,3.31E-08,2.69E-08,1385/253260/6197/5580/8440/2059/5782/6195/9101/3636/8826/9922/10006/1759/8867/10928/2060/5335/4215/6714/9846/6774/30011/2475/6464,25
126,17,WP2380,Brain-derived neurotrophic factor (BDNF) signaling pathway,21/257,144/7850,7.08E-09,2.58E-06,1.05E-06,1385/7074/6197/7249/324/5580/1739/8440/5562/4082/6195/53358/5335/8894/3667/2309/6714/6774/1499/2475/6464,21
127,17,WP3888,VEGFA-VEGFR2 signaling pathway,37/257,439/7850,8.16E-08,2.98E-05,8.07E-06,1385/4301/253260/2889/1495/84952/5587/5580/405/6461/4691/9344/1500/5581/5562/7430/23189/7114/8826/301/8867/2060/9513/9759/5335/26058/2309/2926/100506658/6714/6774/1499/4772/2475/1796/5784/6464,37
128,17,WP4659,Gastrin signaling pathway,16/257,114/7850,7.95E-07,0.000290177,5.90E-05,1385/5587/5580/6548/5581/999/5335/3667/2309/6714/6774/1499/2475/7082/64283/6464,16
129,17,WP4905,1q21.1 copy number variation syndrome,8/257,28/7850,2.08E-06,0.000760342,0.000123672,4301/26108/5562/50848/9414/100506658/1499/7082,8
130,17,WP4537,Hippo-Yap signaling pathway,7/257,23/7850,5.81E-06,0.002120908,0.000287477,50488/6788/23043/4771/26524/23012/9448,7
131,17,WP481,Insulin signaling,17/257,161/7850,1.89E-05,0.006884878,0.000799891,50488/2889/6197/7249/6885/5580/9882/5562/6195/53358/3636/9448/3667/2309/4215/2475/6464,17
132,17,WP2038,Microtubule cytoskeleton regulation,9/257,49/7850,2.45E-05,0.008940098,0.000814138,7074/324/2011/4139/7204/6249/6714/4131/6774,9
133,17,WP3915,Angiopoietin-like protein 8 regulatory pathway,15/257,132/7850,2.47E-05,0.009009653,0.000814138,253260/50488/2889/6197/7249/6885/5562/6195/53358/9448/3667/2309/4215/2475/6464,15
134,17,WP2374,Oncostatin M signaling pathway,10/257,66/7850,4.97E-05,0.018151333,0.001476186,1385/253260/5580/5581/3572/3667/6714/6774/2475/6464,10
135,17,WP3676,BDNF-TrkB signaling,7/257,34/7850,9.36E-05,0.034178643,0.002526939,1385/7249/6195/5335/9846/2475/6464,7
136,17,WP3878,ATM signaling in development and disease ,8/257,46/7850,0.000104889,0.038284514,0.002594625,9656/10155/7249/4361/5562/4683/9759/2475,8
137,17,WP304,Kit receptor signaling pathway,9/257,60/7850,0.000128681,0.04696841,0.002938293,6197/6195/5335/2309/6714/9846/6774/1796/6464,9
138,18,WP4905,1q21.1 copy number variation syndrome,8/265,28/7850,2.62E-06,0.000917668,0.000847291,4301/9414/27134/7082/9557/51422/100506658/1499,8
139,18,WP3888,VEGFA-VEGFR2 signaling pathway,31/265,439/7850,6.88E-05,0.024072108,0.007863984,4301/1500/9513/5747/253260/1386/5717/4691/26058/10963/1981/6924/2035/6194/154796/8650/2113/10397/3315/10755/9645/5321/1267/102/6386/5331/9898/5058/100506658/23215/1499,31
140,18,WP4565,Neural crest cell migration in cancer,8/265,44/7850,9.35E-05,0.032731331,0.007863984,7074/30849/57498/1009/10298/7204/25791/5058,8
141,18,WP2380,Brain-derived neurotrophic factor (BDNF) signaling pathway,15/265,144/7850,9.73E-05,0.034068727,0.007863984,7074/4082/57498/6194/23426/8844/8878/324/6197/8660/6696/7249/10746/6868/1499,15
142,20,WP306,Focal adhesion,16/136,202/7850,3.52E-07,6.94E-05,6.56E-05,83660/7414/7094/858/5829/10298/857/4638/81/4660/3913/2316/55742/7791/4659/2318,16
143,20,WP3888,VEGFA-VEGFR2 signaling pathway,22/136,439/7850,5.57E-06,0.001096335,0.000518438,7414/4860/29109/213/5829/4641/152273/91624/4629/2035/857/2243/5580/2078/3146/3045/389/22899/84952/9209/7001/2697,22
144,20,WP185,Integrin-mediated cell adhesion,10/136,104/7850,1.14E-05,0.002253016,0.000710275,7145/7414/7094/10580/858/5829/10298/857/8874/7791,10
145,20,WP4560,MFAP5 effect on permeability and motility of endothelial cells via cytoskeleton rearrangement,4/136,18/7850,0.000218408,0.043026415,0.010173224,7414/5829/7082/4638,4
146,21,WP437,EGF/EGFR signaling pathway,26/258,164/7850,1.63E-11,6.63E-09,5.11E-09,25/29924/5058/673/6197/6774/6195/160/1173/3725/10617/6198/9101/5598/2064/3636/2060/6464/4690/5747/466/1956/1978/6655/4216/5894,26
147,21,WP673,ErbB signaling pathway,15/258,91/7850,2.20E-07,8.93E-05,3.44E-05,25/5058/673/3725/6198/5062/2064/6464/4690/5747/1956/816/1978/6655/5894,15
148,21,WP2037,Prolactin signaling pathway,13/258,76/7850,9.28E-07,0.000376909,9.67E-05,5058/6774/3725/6198/4790/2064/3688/6464/5829/5747/116986/1978/5894,13
149,21,WP3651,Pathways affected in adenoid cystic carcinoma,11/258,66/7850,8.44E-06,0.003427593,0.000489506,63035/23269/55534/2064/6595/58508/5591/29072/8243/221037/5894,11
150,21,WP306,Focal adhesion,20/258,202/7850,9.67E-06,0.003925801,0.000489506,3691/5058/673/394/2317/3725/7408/5062/2064/2909/3688/329/1793/6464/5829/5747/1956/60/7094/5894,20
151,21,WP313,Hepatocyte growth factor receptor signaling,8/258,34/7850,1.06E-05,0.004285496,0.000489506,5058/6774/3725/3688/1793/5829/5747/5894,8
152,21,WP4549,Fragile X syndrome,15/258,123/7850,1.10E-05,0.00444989,0.000489506,5530/673/4204/4763/160/1173/4131/6198/23426/10243/6464/9743/116986/816/5894,15
153,21,WP3303,RAC1/PAK1/p38/MMP2 pathway,11/258,69/7850,1.31E-05,0.005333372,0.000513356,5058/6774/4790/2064/3688/4690/10318/5829/5747/1956/1978,11
154,21,WP3888,VEGFA-VEGFR2 signaling pathway,32/258,439/7850,1.62E-05,0.006570115,0.000562131,25/5530/4673/29924/5058/4301/6774/2317/160/3725/1982/9588/5954/6198/5062/4790/7086/4217/3688/9578/1500/6595/4646/2060/6464/4690/5829/6924/5747/100506658/8754/5894,32
155,21,WP4205,MET in type 1 papillary renal cell carcinoma,10/258,59/7850,1.87E-05,0.00760854,0.000566913,5058/673/6774/3725/5062/6924/5747/6135/6655/5894,10
156,21,WP4659,Gastrin signaling pathway,14/258,114/7850,1.99E-05,0.008098451,0.000566913,5058/6774/3725/100271849/6198/4790/3688/329/6464/5829/5747/1956/1978/5894,14
157,21,WP185,Integrin-mediated cell adhesion,13/258,104/7850,3.27E-05,0.013284145,0.000852431,3691/5058/673/7408/5062/5598/3688/1793/6464/5829/5747/7094/5894,13
158,21,WP3878,ATM signaling in development and disease ,8/258,46/7850,0.000107773,0.043755836,0.002578477,7158/5932/55183/9656/4790/4217/5591/8243,8
159,21,WP4928,MAPK pathway in congenital thyroid cancer,5/258,16/7850,0.000119665,0.048584117,0.002578477,673/3725/6464/6655/5894,5
160,22,WP3888,VEGFA-VEGFR2 signaling pathway,61/388,439/7850,5.96E-14,2.49E-11,2.18E-11,1495/7414/5605/4627/10014/8867/3315/5580/91624/2534/1500/357/4629/213/5606/152273/8650/23215/2889/9734/6416/9475/25/2060/7410/867/5770/7114/5295/5829/9759/5331/29766/51564/7430/4217/10645/1213/1465/7019/11080/6386/9564/1397/5578/5908/3303/10973/4846/2549/29109/1398/2035/1466/9444/5717/8775/4772/274/100506658/4301,61
161,22,WP481,Insulin signaling,30/388,161/7850,1.91E-10,7.98E-08,3.51E-08,5605/5607/5580/5606/5871/2889/6416/867/5770/5295/8491/5286/50488/4215/4217/5211/5588/11127/11184/5578/8773/10580/2549/1398/23678/9448/10211/10603/10938/1326,30
162,22,WP51,Regulation of actin cytoskeleton,23/388,151/7850,1.20E-06,0.000498794,0.000124907,10458/7414/6548/5605/4638/4628/4659/5159/9475/10163/4478/8395/7114/5295/5829/5286/87/7430/60/2258/9564/1398/28964,23
163,22,WP382,MAPK signaling pathway,31/388,249/7850,1.62E-06,0.000676164,0.000124907,5532/2316/5605/5607/3315/5580/5567/408/5566/10000/5606/5871/6416/5159/8491/3925/775/10235/4217/2258/11184/5578/5908/5495/3303/1398/9448/57551/4772/3312/1326,31
164,22,WP3915,Angiopoietin-like protein 8 regulatory pathway,21/388,132/7850,1.70E-06,0.000710945,0.000124907,5605/5607/5606/5871/2889/6416/867/5770/5564/5295/8491/7067/5286/50488/4215/4217/11184/1398/9448/10211/1326,21
165,22,WP289,Myometrial relaxation and contraction pathways,22/388,158/7850,9.23E-06,0.003849356,0.000515608,5580/3710/5567/408/5566/5577/800/801/5576/5331/7534/10636/5588/816/818/60/5578/115/5998/5573/4846/1264,22
166,22,WP2272,Pathogenic Escherichia coli infection,12/388,55/7850,1.14E-05,0.004747176,0.000515608,2534/10382/9475/25/7277/7534/2017/7430/60/5578/3875/100506658,12
167,22,WP185,Integrin-mediated cell adhesion,17/388,104/7850,1.16E-05,0.004819436,0.000515608,7414/7145/5605/5607/7094/2534/10000/5606/2889/9475/7410/5829/9564/5908/10580/7408/1398,17
168,22,WP4560,MFAP5 effect on permeability and motility of endothelial cells via cytoskeleton rearrangement,7/388,18/7850,1.35E-05,0.005640169,0.000515608,7414/4638/5829/87/5588/7082/4026,7
169,22,WP536,Calcium regulation in cardiac cells,21/388,152/7850,1.67E-05,0.006949481,0.000515608,5580/3710/5567/408/5566/5577/801/490/5576/309/5331/775/7534/10636/5588/816/818/5578/115/5998/5573,21
170,22,WP2795,Cardiac hypertrophic response,12/388,57/7850,1.68E-05,0.006995849,0.000515608,5605/5607/10014/5606/801/9734/6416/4205/9759/51564/11184/5578,12
171,22,WP437,EGF/EGFR signaling pathway,22/388,164/7850,1.69E-05,0.007043384,0.000515608,5605/5607/8867/5580/25/2060/7410/867/5295/1173/4205/2059/4209/3925/4215/9564/11184/5578/4846/2549/1398/5037,22
172,22,WP306,Focal adhesion,25/388,202/7850,1.88E-05,0.007838404,0.000529668,81/7414/2316/4638/7094/2534/10000/4659/2889/7448/5159/9475/7410/3912/5295/5829/87/4660/60/9564/5578/5908/7408/1398/3055,25
173,22,WP2261,Glioblastoma signaling pathways,14/388,83/7850,4.79E-05,0.019955252,0.001252128,5605/5607/5580/10000/5606/6416/5159/867/5295/5286/5588/5578/2549/5925,14
174,22,WP3965,Lipid metabolism pathway,8/388,29/7850,5.69E-05,0.023709677,0.001388526,5567/5566/5577/10000/5576/5564/5346/5573,8
175,22,WP35,G protein signaling pathways,15/388,97/7850,7.35E-05,0.030641263,0.001682311,6548/5580/5567/5566/5577/801/5576/5331/9590/5588/5578/11214/115/5573/11216,15
176,22,WP366,TGF-beta signaling pathway,18/388,133/7850,8.79E-05,0.036646883,0.001893685,1601/5605/6711/9839/6497/5606/6416/7041/10413/5576/5295/4205/6498/9564/11184/10987/9972/55802,18
177,22,WP2038,Microtubule cytoskeleton regulation,10/388,49/7850,0.000112555,0.04693552,0.002290597,90102/5566/1808/25/3925/4139/5578/57551/4131/5786,10
178,23,WP411,mRNA processing,26/338,133/7850,5.33E-11,2.04E-08,1.86E-08,22803/10181/27316/23451/6429/8449/3183/10291/8899/10946/3187/3188/5496/4670/3184/6430/10772/10914/57396/3192/10250/6627/3181/1198/1653/6431,26
179,23,WP3651,Pathways affected in adenoid cystic carcinoma,15/338,66/7850,8.64E-08,3.30E-05,1.51E-05,23269/29072/58508/51742/221037/10847/63035/5591/5605/546/64324/84159/9874/472/5894,15
180,23,WP3878,ATM signaling in development and disease ,12/338,46/7850,3.47E-07,0.000132371,4.02E-05,3150/7158/64421/55183/10155/5591/10524/545/3930/9656/7249/472,12
181,23,WP2369,Histone modifications,13/338,70/7850,7.12E-06,0.00272142,0.00062055,7799/9757/2145/29072/58508/10919/6418/64324/84444/83852/55209/8085/4297,13
182,23,WP2916,Interactome of polycomb repressive complex 2 (PRC2) ,6/338,17/7850,5.04E-05,0.01925147,0.003511842,9967/9774/23087/2145/5928/23064,6
183,23,WP3959,DNA IR-double strand breaks and cellular response via ATM,10/338,55/7850,9.93E-05,0.037940448,0.005767561,7158/64421/55183/9126/10155/5591/10524/545/9656/472,10
184,24,WP411,mRNA processing,17/217,133/7850,1.24E-07,4.16E-05,3.88E-05,11129/6434/6625/9129/3178/3182/5725/6421/5094/11218/10250/5430/10236/84991/24148/22803/55660,17
185,24,WP4016,DNA IR-damage and cellular response via ATR,11/217,83/7850,1.57E-05,0.005261726,0.002455196,6601/9656/4171/9400/4361/7158/7486/995/983/5932/5591,11
186,24,WP2446,Retinoblastoma gene in cancer,11/217,88/7850,2.76E-05,0.009242297,0.002471337,9133/54443/5925/2956/24137/983/4172/5591/25942/4173/7029,11
187,24,WP3878,ATM signaling in development and disease ,8/217,46/7850,3.16E-05,0.010592632,0.002471337,9656/4361/7158/55183/4790/983/5932/5591,8
188,25,WP411,mRNA processing,24/347,133/7850,2.85E-09,1.05E-06,9.34E-07,23451/8449/5430/10236/11129/27316/6733/1478/3187/3181/10914/8899/10250/8175/10291/10992/1198/57794/22803/6434/3183/6426/8683/6433,24
189,25,WP2446,Retinoblastoma gene in cancer,16/347,88/7850,1.19E-06,0.00043878,0.000195263,4863/2956/5931/5426/10714/9126/24137/7029/5925/6118/4998/1786/5894/8030/4175/6241,16
190,25,WP5049,Glycolysis in senescence,6/347,Nov-50,2.74E-06,0.001009349,0.00029945,5315/5925/5230/2597/2023/3939,6
191,25,WP4629,Aerobic glycolysis,6/347,Dec-50,5.27E-06,0.001943744,0.000432498,5315/5230/2597/2023/226/3939,6
192,25,WP2369,Histone modifications,12/347,70/7850,4.82E-05,0.017790985,0.003166902,84444/7799/29072/9739/83852/8085/58508/9757/55870/64324/84193/4297,12
193,25,WP3651,Pathways affected in adenoid cystic carcinoma,11/347,66/7850,0.000129558,0.047806876,0.007091592,29072/672/10847/546/5605/58508/64324/5894/2033/1387/55914,11
194,26,WP437,EGF/EGFR signaling pathway,21/229,164/7850,9.67E-09,3.65E-06,1.53E-06,5580/1432/2549/3727/58513/5781/5335/10928/9846/5594/857/6774/6776/3725/9185/3925/9712/5579/1399/5782/4734,21
195,26,WP3888,VEGFA-VEGFR2 signaling pathway,36/229,439/7850,1.21E-08,4.54E-06,1.53E-06,2243/5580/2035/152273/1432/2549/10818/10973/5781/9898/5335/5581/100506658/5595/5594/857/6774/1500/5829/1213/91624/23215/4629/7414/4301/5062/3725/3315/29109/3164/5579/84335/84952/653361/2317/3045,36
196,26,WP4560,MFAP5 effect on permeability and motility of endothelial cells via cytoskeleton rearrangement,8/229,18/7850,1.58E-08,5.96E-06,1.53E-06,4638/5335/5595/5594/5829/7414/3725/87,8
197,26,WP304,Kit receptor signaling pathway,12/229,60/7850,1.16E-07,4.36E-05,8.39E-06,1432/5781/5335/9846/5595/5594/6774/6776/6909/5579/4137/1399,12
198,26,WP49,IL-2 signaling pathway,10/229,42/7850,2.38E-07,8.97E-05,1.38E-05,5781/9846/5595/5594/6774/6776/3725/6199/4137/1399,10
199,26,WP1528,Physiological and pathological hypertrophy of the heart,8/229,25/7850,3.27E-07,0.000123312,1.55E-05,1432/5581/5594/6774/3725/3977/817/5579,8
200,26,WP306,Focal adhesion,21/229,202/7850,3.73E-07,0.000140543,1.55E-05,2316/4638/2318/5595/5594/857/5829/54776/7408/7414/5062/3725/7094/7448/7791/87/5579/103910/1399/4659/2317,21
201,26,WP2374,Oncostatin M signaling pathway,11/229,66/7850,2.67E-06,0.001008399,9.71E-05,5580/1432/3727/5781/5581/5595/5594/6774/5829/3977/5579,11
202,26,WP313,Hepatocyte growth factor receptor signaling,8/229,34/7850,4.37E-06,0.001649238,0.000141216,2549/5781/5595/5594/6774/5829/3725/1399,8
203,26,WP4205,MET in type 1 papillary renal cell carcinoma,10/229,59/7850,6.58E-06,0.00247887,0.000191028,2549/5781/5335/5546/5595/5594/6774/5062/3725/1399,10
204,26,WP673,ErbB signaling pathway,12/229,91/7850,1.17E-05,0.004415324,0.000309324,2549/5335/5595/5594/6776/5062/3725/817/6199/5579/1399/2065,12
205,26,WP127,IL-5 signaling pathway,8/229,40/7850,1.59E-05,0.006005371,0.000383156,5781/5595/5594/6774/6776/3725/6199/4137,8
206,26,WP2380,Brain-derived neurotrophic factor (BDNF) signaling pathway,15/229,144/7850,1.80E-05,0.006774551,0.000383156,4082/5580/1432/10818/5781/5335/8844/5595/5594/6774/6776/3725/4137/653361/324,15
207,26,WP2324,AGE/RAGE pathway,10/229,66/7850,1.85E-05,0.006960809,0.000383156,5580/4478/1432/5595/5594/6774/6776/3725/5579/653361,10
208,26,WP4659,Gastrin signaling pathway,13/229,114/7850,2.51E-05,0.009463657,0.000468729,5580/1432/5781/5335/960/5581/1113/5595/5594/6774/5829/3725/302,13
209,26,WP395,IL-4 signaling pathway,9/229,55/7850,2.58E-05,0.0097319,0.000468729,2316/1432/5781/9846/5595/5594/6774/6776/4783,9
210,26,WP2572,Primary focal segmental glomerulosclerosis (FSGS),10/229,74/7850,5.13E-05,0.019324871,0.000876016,1028/5335/7431/11346/23607/7414/7225/7094/7448/50485,10
211,26,WP69,T-cell receptor (TCR) signaling pathway,11/229,91/7850,6.20E-05,0.023392273,0.000989636,5580/1432/5781/5335/7431/9846/5595/5594/3725/28988/1399,11
212,26,WP2037,Prolactin signaling pathway,10/229,76/7850,6.47E-05,0.024399724,0.000989636,2316/1432/5781/9846/5595/5594/6774/5829/6776/3725,10
213,26,WP286,IL-3 signaling pathway,8/229,49/7850,7.45E-05,0.028082125,0.001082042,5781/9846/5595/5594/6774/6776/3725/1399,8
214,27,WP437,EGF/EGFR signaling pathway,36/433,164/7850,4.08E-13,1.77E-10,1.43E-10,29924/2308/9712/50807/4209/5605/5782/4303/3727/3925/2185/9138/2353/3635/5894/6774/4846/6776/2002/6197/3985/2059/58513/2549/867/1398/6198/9610/2354/4215/6654/5287/6714/5747/8826/5578,36
215,27,WP3888,VEGFA-VEGFR2 signaling pathway,62/433,439/7850,2.68E-12,1.16E-09,4.70E-10,4301/29924/8650/2243/274/2308/10645/7414/9444/1495/29109/2035/2876/5605/2113/5581/4217/4303/10525/9588/357/2185/4688/5894/5606/1499/6774/1827/23196/4846/6595/226/1500/2002/6461/7430/5970/1386/6624/5226/2549/867/1398/6198/9578/9209/84952/213/3164/2889/653361/5587/23476/11124/6714/5829/5747/100506658/8826/2597/5578/2317,62
216,27,WP304,Kit receptor signaling pathway,18/433,60/7850,1.70E-09,7.36E-07,1.98E-07,2033/5605/2353/3635/5894/6774/695/6776/4137/6197/867/1398/6198/572/6654/6714/2886/5578,18
217,27,WP4659,Gastrin signaling pathway,24/433,114/7850,9.09E-09,3.95E-06,7.97E-07,2308/7082/4209/5581/5583/2353/5894/1499/6774/5588/2002/5970/6548/1386/1398/6198/4296/572/6654/5587/6714/5829/5747/5578,24
218,27,WP313,Hepatocyte growth factor receptor signaling,13/433,34/7850,1.17E-08,5.09E-06,8.22E-07,5605/2185/2353/5894/6774/2002/2549/1398/2889/6654/6714/5829/5747,13
219,27,WP395,IL-4 signaling pathway,15/433,55/7850,1.62E-07,7.03E-05,8.52E-06,2033/8660/2316/2353/3635/6774/6776/2002/5970/1386/867/6198/2242/572/6654,15
220,27,WP481,Insulin signaling,27/433,161/7850,1.70E-07,7.39E-05,8.52E-06,5603/5871/2308/8660/8773/5605/4217/5583/2353/5894/5606/5588/2002/6236/6197/2549/867/1398/6198/4296/7248/4215/2889/6654/30846/5578/8986,27
221,27,WP2380,Brain-derived neurotrophic factor (BDNF) signaling pathway,25/433,144/7850,2.48E-07,0.000107694,1.09E-05,8660/6868/5605/4082/2185/1739/2353/4688/5894/1499/6774/25970/6776/2002/5970/4137/6197/6792/1457/10018/4776/6198/572/653361/6714,25
222,27,WP4205,MET in type 1 papillary renal cell carcinoma,14/433,59/7850,2.64E-06,0.001146466,0.000102884,5605/2113/5894/6774/2549/867/1398/572/2889/6654/7030/6714/5747/10298,14
223,27,WP23,B cell receptor signaling pathway,18/433,98/7850,5.36E-06,0.00232802,0.000188026,2308/4209/2969/5605/2113/3635/5894/695/2002/5970/1386/604/2549/867/1398/2889/6654/3059,18
224,27,WP673,ErbB signaling pathway,17/433,91/7850,7.72E-06,0.003350374,0.000245998,2308/5605/5894/6776/2002/10018/2549/867/1398/6198/572/6654/6714/5747/5578/10298/27,17
225,27,WP2038,Microtubule cytoskeleton regulation,12/433,49/7850,9.72E-06,0.00421672,0.000283808,57551/90102/7204/4131/3925/6774/6249/4137/5786/6714/5578/4139,12
226,27,WP2034,Leptin signaling pathway,15/433,76/7850,1.33E-05,0.005753829,0.00033194,2308/5605/5894/6774/5140/25970/4846/2002/5970/6198/8648/572/6654/6714/5747,15
227,27,WP2037,Prolactin signaling pathway,15/433,76/7850,1.33E-05,0.005753829,0.00033194,8660/2316/5605/2353/5894/6774/6776/2002/5970/867/6198/6654/6714/5829/5747,15
228,27,WP3303,RAC1/PAK1/p38/MMP2 pathway,14/433,69/7850,1.85E-05,0.008020535,0.00043186,5603/2308/3925/1499/6774/6776/5970/1398/572/6654/6714/2886/5829/5747,14
229,27,WP51,Regulation of actin cytoskeleton,22/433,151/7850,2.48E-05,0.010769555,0.00053919,4638/7414/8874/2934/28964/5605/10458/54434/2909/9138/8396/5894/7430/6548/1398/6654/5287/5829/5747/87/8826/10298,22
230,27,WP3879,"4-hydroxytamoxifen, Dexamethasone, and Retinoic Acids Regulation of p27 Expression",7/433,18/7850,2.77E-05,0.01201665,0.00053919,5605/4217/5894/5606/4296/7248/2872,7
231,27,WP4560,MFAP5 effect on permeability and motility of endothelial cells via cytoskeleton rearrangement,7/433,18/7850,2.77E-05,0.01201665,0.00053919,4638/7414/7082/5588/5829/5747/87,7
232,27,WP366,TGF-beta signaling pathway,20/433,133/7850,3.64E-05,0.015808112,0.000671981,3691/2033/6711/5371/5576/5605/2113/150094/3727/2353/5894/5606/25942/1386/3985/1601/2354/6654/6714/5747,20
233,27,WP127,IL-5 signaling pathway,10/433,40/7850,4.46E-05,0.019365676,0.000782048,5605/2353/5894/6774/695/6776/2002/4137/6198/6654,10
234,27,WP185,Integrin-mediated cell adhesion,17/433,104/7850,4.75E-05,0.020614207,0.000792827,3691/7094/7414/8874/5605/7145/5894/5606/826/1398/823/2889/6654/6714/5829/5747/10298,17
235,27,WP2374,Oncostatin M signaling pathway,13/433,66/7850,5.10E-05,0.022148031,0.000813099,5605/5581/5583/3727/2185/2353/5894/6774/5970/6654/6714/5829/5578,13
236,27,WP49,IL-2 signaling pathway,10/433,42/7850,7.01E-05,0.030434857,0.001068746,5605/2185/2353/5894/6774/6776/4137/867/6198/6654,10
237,27,WP382,MAPK signaling pathway,29/433,249/7850,0.000100137,0.043459559,0.001462531,5603/5871/57551/2318/2316/5605/4217/3727/3925/2353/5894/5606/2002/5971/5970/4137/1386/6197/115727/1398/4296/80824/2872/3164/4791/6654/5578/2317/8986,29
238,28,WP306,Focal adhesion,24/199,202/7850,2.05E-10,6.14E-08,5.28E-08,7410/7094/10451/858/87/2317/4638/5578/7414/7791/10298/2268/81/2316/10398/5747/55742/1398/5829/857/3611/2534/2318/10000,24
239,28,WP185,Integrin-mediated cell adhesion,16/199,104/7850,5.95E-09,1.78E-06,7.67E-07,7410/7145/7094/10451/858/10580/7414/7791/10298/5747/1398/5829/857/3611/2534/10000,16
240,28,WP3888,VEGFA-VEGFR2 signaling pathway,31/199,439/7850,1.60E-07,4.80E-05,1.38E-05,7410/4629/84952/5580/91624/2317/7430/5590/5581/5578/274/7414/2697/2035/26058/22899/5592/301/660/2078/357/152273/2549/5747/2243/1398/5829/3045/857/4641/2534,31
241,28,WP2572,Primary focal segmental glomerulosclerosis (FSGS),12/199,74/7850,2.80E-07,8.39E-05,1.80E-05,11346/7094/7431/3987/7402/5420/7414/81/5747/55742/3611/2534,12
242,28,WP4560,MFAP5 effect on permeability and motility of endothelial cells via cytoskeleton rearrangement,6/199,18/7850,3.54E-06,0.001063185,0.000182793,7082/87/4638/7414/5747/5829,6
243,28,WP4659,Gastrin signaling pathway,12/199,114/7850,2.90E-05,0.008689295,0.001244957,7082/5580/302/5581/5578/408/5747/1398/5829/5583/6925/2534,12
244,28,WP51,Regulation of actin cytoskeleton,13/199,151/7850,0.000112103,0.033630829,0.004130102,4628/8045/87/7430/4638/7414/10298/28964/9459/5747/1398/5829/4478,13
245,28,WP35,G protein signaling pathways,10/199,97/7850,0.000161484,0.048445069,0.00520572,9590/5580/5590/5581/5578/5137/801/5143/5583/10142,10
246,29,WP437,EGF/EGFR signaling pathway,33/465,164/7850,3.30E-10,1.44E-07,1.18E-07,2064/5868/8202/8867/4605/1072/3635/29924/6311/4208/5782/9138/2060/868/30011/5747/6197/673/4214/5337/3985/4209/3925/25/2887/1173/8440/58513/10746/6714/5781/5579/5598,33
247,29,WP3888,VEGFA-VEGFR2 signaling pathway,56/465,439/7850,2.50E-08,1.09E-05,4.46E-06,2597/71/84335/1981/54505/5868/10645/8867/55854/8569/1072/4301/5777/2746/6181/29924/54205/1500/2309/23196/25865/26058/4208/2060/5226/22820/811/2317/5230/5747/5034/3998/1495/9578/9444/8667/115098/3315/4627/10628/23476/2314/25/1499/2887/56905/6714/5216/4217/5781/2624/11124/1192/5579/357/3303,56
248,29,WP366,TGF-beta signaling pathway,24/465,133/7850,7.60E-07,0.000330398,6.78E-05,9972/22938/64219/5934/23327/5371/8021/4609/3691/4208/5933/5747/4233/3985/2033/25942/10413/79753/10454/6714/8312/983/9133/57559,24
249,29,WP411,mRNA processing,24/465,133/7850,7.60E-07,0.000330398,6.78E-05,6432/1198/10147/5094/6421/3181/10946/1478/10421/6430/6434/6433/8899/23451/10250/23283/6429/22803/5430/4841/10992/57794/9128/24148,24
250,29,WP3651,Pathways affected in adenoid cystic carcinoma,15/465,66/7850,5.04E-06,0.002191992,0.00035963,58508/9611/2064/10847/23269/4609/2309/8289/29072/51742/6605/7994/2033/55914/221037,15
251,29,WP2380,Brain-derived neurotrophic factor (BDNF) signaling pathway,23/465,144/7850,1.10E-05,0.004803583,0.000656751,814/3667/8878/1072/8660/2309/4776/4208/8536/6197/3551/4214/4082/1499/324/8440/10746/1808/6714/1739/5781/10603/5598,23
252,29,WP4018,Clear cell renal cell carcinoma pathways,16/465,87/7850,4.22E-05,0.018347472,0.002150132,2597/26227/84335/8314/7248/8878/2194/8536/4190/5230/29072/57521/3101/2033/2023/2887,16
253,29,WP61,Notch signaling pathway (Netpath),13/465,63/7850,6.39E-05,0.027783438,0.002848937,9611/22938/7088/4609/9794/9253/3932/3714/23013/4853/2033/84441/6714,13
254,29,WP138,Androgen receptor signaling pathway,16/465,91/7850,7.45E-05,0.032388834,0.002881291,9611/8202/2316/811/5747/10524/6605/3985/10499/2033/25942/1499/24149/5925/6714/56924,16
255,29,WP4534,Mechanoregulation and pathology of YAP/TAZ via Hippo and non-Hippo mechanisms,11/465,48/7850,8.56E-05,0.037215975,0.002881291,71/9448/60/8491/3691/10298/1495/9113/1499/6714/56924,11
256,29,WP3915,Angiopoietin-like protein 8 regulatory pathway,20/465,132/7850,8.88E-05,0.038636068,0.002881291,9448/5286/3667/7248/8660/8491/2309/4296/2194/5597/51085/868/30849/6197/57521/4214/8986/10746/4217/5598,20
257,30,WP437,EGF/EGFR signaling pathway,22/279,164/7850,6.61E-08,2.53E-05,2.18E-05,9712/10746/2697/50807/5584/3635/5579/6654/4605/6774/998/5037/160/5170/9101/25/5782/5295/868/5335/2059/4690,22
258,30,WP3888,VEGFA-VEGFR2 signaling pathway,33/279,439/7850,3.20E-05,0.012257799,0.005272353,2746/84335/2697/2317/4629/9475/22926/405/5584/4691/226/5579/4627/6774/998/5062/6722/1495/160/5170/9451/23476/1500/1969/25/1387/5295/1827/5335/1499/4690/1192/5226,33
259,30,WP3651,Pathways affected in adenoid cystic carcinoma,10/279,66/7850,9.92E-05,0.03798066,0.010890886,472/29072/9611/26292/546/23269/54880/51742/1387/64324,10